-
Research ethics: Not applicable.
-
Informed consent: Not applicable.
-
Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: The authors state no conflict of interest.
-
Research funding: None declared.
References
1. Wojdala, AL, Bellomo, G, Toja, A, Gaetani, L, Parnetti, L, Chiasserini, D. CSF and plasma Abeta42/40 across Alzheimer’s disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions. Clin Chem Lab Med 2023;62:332–40.https://doi.org/10.1515/cclm-2023-0659 Search in Google Scholar PubMed
2. Klafki, HW, Morgado, B, Wirths, O, Jahn, O, Bauer, C, Esselmann, H, et al.. Is plasma amyloid-beta 1-42/1-40 a better biomarker for Alzheimer’s disease than AbetaX-42/X-40? Fluids Barriers CNS 2022;19:96. https://doi.org/10.1186/s12987-022-00390-4.Search in Google Scholar PubMed PubMed Central
3. Ovod, V, Ramsey, KN, Mawuenyega, KG, Bollinger, JG, Hicks, T, Schneider, T, et al.. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s Dementia 2017;13:841–9. https://doi.org/10.1016/j.jalz.2017.06.2266.Search in Google Scholar PubMed PubMed Central
4. Roher, AE, Esh, CL, Kokjohn, TA, Castano, EM, Van Vickle, GD, Kalback, WM, et al.. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s Dementia 2009;5:18–29. https://doi.org/10.1016/j.jalz.2008.10.004.Search in Google Scholar PubMed PubMed Central
5. Keshavan, A, Wellington, H, Chen, Z, Khatun, A, Chapman, M, Hart, M, et al.. Concordance of CSF measures of Alzheimer’s pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays. Alzheimer’s Dementia 2021;13:e12131. https://doi.org/10.1002/dad2.12131.Search in Google Scholar PubMed PubMed Central
6. Schindler, SE, Bollinger, JG, Ovod, V, Mawuenyega, KG, Li, Y, Gordon, BA, et al.. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019;93:e1647–59. https://doi.org/10.1212/wnl.0000000000008081.Search in Google Scholar
7. Vigo-Pelfrey, C, Lee, D, Keim, P, Lieberburg, I, Schenk, DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993;61:1965–8. https://doi.org/10.1111/j.1471-4159.1993.tb09841.x.Search in Google Scholar PubMed
8. Portelius, E, Westman-Brinkmalm, A, Zetterberg, H, Blennow, K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 2006;5:1010–6. https://doi.org/10.1021/pr050475v.Search in Google Scholar PubMed
9. Portelius, E, Zetterberg, H, Andreasson, U, Brinkmalm, G, Andreasen, N, Wallin, A, et al.. An Alzheimer’s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006;409:215–9. https://doi.org/10.1016/j.neulet.2006.09.044.Search in Google Scholar PubMed
10. Portelius, E, Tran, AJ, Andreasson, U, Persson, R, Brinkmalm, G, Zetterberg, H, et al.. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007;6:4433–9. https://doi.org/10.1021/pr0703627.Search in Google Scholar PubMed
11. Cabrera, E, Mathews, P, Mezhericher, E, Beach, TG, Deng, J, Neubert, TA, et al.. Abeta truncated species: implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis 2018;1864:208–25. https://doi.org/10.1016/j.bbadis.2017.07.005.Search in Google Scholar PubMed PubMed Central
12. Gelfanova, V, Higgs, RE, Dean, RA, Holtzman, DM, Farlow, MR, Siemers, ER, et al.. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Briefings Funct Genomics Proteomics 2007;6:149–58. https://doi.org/10.1093/bfgp/elm010.Search in Google Scholar PubMed
13. McIntee, FL, Giannoni, P, Blais, S, Sommer, G, Neubert, TA, Rostagno, A, et al.. In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer’s Abeta protein. Front Aging Neurosci 2016;8:223. https://doi.org/10.3389/fnagi.2016.00223.Search in Google Scholar PubMed PubMed Central
14. Maler, JM, Klafki, HW, Paul, S, Spitzer, P, Groemer, TW, Henkel, AW, et al.. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 2007;7:3815–20. https://doi.org/10.1002/pmic.200700311.Search in Google Scholar PubMed
15. Kaneko, N, Yamamoto, R, Sato, TA, Tanaka, K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Jpn Acad Ser B Phys Biol Sci 2014;90:104–17. https://doi.org/10.2183/pjab.90.104.Search in Google Scholar PubMed PubMed Central
© 2023 Walter de Gruyter GmbH, Berlin/Boston
